Platelet-rich plasma is a coagulated blood-rich polymer, made from extracted platelets. Extracted platelets are normally coagulated by monocytes or lymphocytes with fibrin. Platelets are also commonly injected into the body's bloodstream to support tissue healing following tissue surgery. Platelet-rich plasma has been found effective against bleeding disorders. It also helps reduce the risk of deep vein thrombosis (DVT) in patients with high blood pressure and in those taking anticoagulants. It may also reduce the risk of pulmonary embolism (PE), which is blood clots that enter the lungs and pulmonary system. In the chest, the clot can stop or limit the flow of blood to the heart. PE often leads to cardiac arrest and death.
Increasing cosmetic surgeries is expected to drive growth of the global platelet rich plasma market during the forecast period. Cosmetic surgeries refer to surgical specialty involving the restoration, alteration, or reconstruction of the human body. According to the International Society of Aesthetic Plastic Surgery (ISAPS), in 2018, around 128,398 cosmetic procedures in Thailand and 1,036,618 procedures in Mexico were carried out. Hence, these factors are expected to drive growth of the global platelet rich plasma market during the forecast period. Furthermore, increasing prevalence of cosmetic surgeries is expected to boost the global platelet rich plasma market growth over the forecast period.
However, uncertainty regarding the efficiency of platelet-rich plasma products combined with the high cost of these products is expected to hinder the global platelet rich plasma market growth over the forecast period. Besides, continuous R&D activities in the field of plasma-rich bioactive molecules can present lucrative growth opportunities in the global platelet rich plasma market in the near future. Among regions, North America is expected to hold a dominant position in the global platelet rich plasma market during the forecast period. This is owing to increasing number of people suffering from orthopedic disorders. Furthermore, Asia Pacific is expected to register a robust growth rate over the forecast period, owing to rising number of cosmetic surgeries facial features in emerging economies such as Thailand, India, and South Korea.
Key players operating in the global platelet rich plasma market are Estar Technologies Ltd., Arthrex, Inc., Generex Biotechnology Corporation, Stryker Corporation, Regen Lab S.A., Johnson and Johnsons Ltd., CollPlant, Zimmer Biomet Holdings Inc., Medira Ltd., Terumo Corporation, and Glofinn Oy.
For instance, in July 2019, Generex Biotechnology Corporation, a U.S.-based healthcare company, acquired Medisource Partners, a provider of medical and surgical products to process bone marrow aspirates and platelet rich plasma biologics.
No comments:
Post a Comment